IL6 and rheumatoid arthritis: The fact that naïve MSCs are IL-6R-negative and induced to express the receptor upon exposure to IRISOE TNBC cells IL-6-rich CM is important since it suggests that like Anakinra, IL-6 inhibitors, such as “Tocilizumab,” the monoclonal antibody (mAb) specific for the IL-6 receptor (IL-6R) currently in late phase clinical trials for rheumatoid arthritis [55], is another valid combinatorial drug to be used with IRIS-pep (or drug “in progress”) to treat women with IRISOE TNBC tumors.